{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:22:37Z","timestamp":1789014157788,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jtct.2024.04.017","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T15:22:48Z","timestamp":1714490568000},"page":"714-725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Chimeric Antigen Receptor T-Cell Access in Patients with Relapsed\/Refractory Large B-Cell Lymphoma: Association of Access with Social Determinants of Health and Travel Time to Treatment Centers"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-4982","authenticated-orcid":false,"given":"Nausheen","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4887-8077","authenticated-orcid":false,"given":"Christie","family":"Teigland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1103-2107","authenticated-orcid":false,"given":"Karl M.","family":"Kilgore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dieyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoling","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Osborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-7385","authenticated-orcid":false,"given":"Usama","family":"Gergis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.04.017_bib0001","unstructured":"SEER 2020 Cancer stat fact: diffuse large B-cell lymphoma. National Cancer Institute. https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html"},{"key":"10.1016\/j.jtct.2024.04.017_bib0002","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.04.017_bib0003","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-Like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomized study of the MabThera International Trial (MinT) group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2024.04.017_bib0004","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.017_bib0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.jtct.2024.04.017_bib38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jtct.2024.04.017_bib0006","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B Cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"16_Suppl","key":"10.1016\/j.jtct.2024.04.017_bib0007","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.7571","article-title":"Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity","volume":"40","author":"Locke","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2024.04.017_bib0008","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"20","key":"10.1016\/j.jtct.2024.04.017_bib0009","doi-asserted-by":"crossref","first-page":"7330","DOI":"10.1002\/cam4.4249","article-title":"Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United States","volume":"10","author":"Vaughn","year":"2021","journal-title":"Cancer Med"},{"issue":"21","key":"10.1016\/j.jtct.2024.04.017_bib0010","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1002\/cncr.33779","article-title":"Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphoma","volume":"127","author":"Hu","year":"2021","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.jtct.2024.04.017_bib0011","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2013-07-517110","article-title":"Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era","volume":"123","author":"Tao","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2024.04.017_bib0012","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1634\/theoncologist.2015-0110","article-title":"Distance as a barrier to cancer diagnosis and treatment: review of the literature","volume":"20","author":"Ambroggi","year":"2015","journal-title":"Oncologist"},{"issue":"22","key":"10.1016\/j.jtct.2024.04.017_bib0013","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.19.00175","article-title":"Impact of travel time on health care costs and resource use by phase of care for older patients with cancer","volume":"37","author":"Rocque","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.04.017_bib0014","unstructured":"Kite Pharma, Inc. YESCARTA (axicabtagene ciloleucel) prescribing information 2022. Available at:https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/yescarta\/yescarta-pi.pdf. Accessed June 21, 2023."},{"key":"10.1016\/j.jtct.2024.04.017_bib0015","unstructured":"Novartis Pharmaceuticals Corporation. KYMRIAH (tisagenlecleucel) prescribing information 2022. Available at: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/kymriah.pdf. Accessed June 21, 2023."},{"key":"10.1016\/j.jtct.2024.04.017_bib0016","unstructured":"Bristol Myers Squibb. BREYANZI (lisocabtagene maraleucel) prescribing information 2022. Available at:https:\/\/packageinserts.bms.com\/pi\/pi_breyanzi.pdf. Accessed June 21, 2023."},{"issue":"1","key":"10.1016\/j.jtct.2024.04.017_bib0017","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1200\/OP.21.00312","article-title":"Willingness to travel for cellular therapy: the influence of follow-up care location, oncologist continuity, and race","volume":"18","author":"Frosch","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"9","key":"10.1016\/j.jtct.2024.04.017_bib0018","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1007\/s12325-021-01838-z","article-title":"Access to chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma","volume":"38","author":"Snyder","year":"2021","journal-title":"Adv Ther"},{"issue":"7","key":"10.1016\/j.jtct.2024.04.017_bib0019","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.04.017_bib0020","series-title":"Presented at: 64th American Society of Hematology Annual Meeting and Exposition","article-title":"Examination of disparities in access to chimeric antigen receptor (CAR) T cell therapies in Medicare patients (pts) with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) who had failed at least 2 prior lines of therapy (LOT)","author":"Saunders","year":"2022"},{"key":"10.1016\/j.jtct.2024.04.017_bib0021","unstructured":"MORE\u00b2 Registry\u00ae Overview (2023). Available at:https:\/\/www.inovalon.com\/products\/data-cloud\/real-world-data\/. Accessed June 16, 2023."},{"key":"10.1016\/j.jtct.2024.04.017_bib0022","unstructured":"Acxiom Corporation (2020). ZIP+4 InfoBase\u00ae Geo Files: demographic, financial and property, Sept 2019 release; Market Indices ACS, Feb 2019 release. Available at: https:\/\/www.acxiom.com. Accessed June 16, 2023."},{"key":"10.1016\/j.jtct.2024.04.017_bib0023","series-title":"Poster presentation PRM50 at the ISPOR 23rd Annual International Meeting","article-title":"Using aggregate data to proxy individual-level characteristics in health services research: 9-digit zipcode vs. Census Block Group. Value in Health 2018; 21: S218-9","author":"Kilgore","year":"2018"},{"key":"10.1016\/j.jtct.2024.04.017_bib0024","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3389\/fonc.2018.00375","article-title":"Increased risk of hepatocellular carcinoma associated with neighborhood concentrated disadvantage","volume":"8","author":"Danos","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2024.04.017_bib37","unstructured":"National Comprehensive Cancer Network\u00ae Clinical Practice Guidelines in Oncology. B-Cell Lymphomas (version 5.2022). https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1480. Accessed June 16, 2023."},{"issue":"6","key":"10.1016\/j.jtct.2024.04.017_bib0025","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.jtct.2024.04.017_bib0026","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"12","key":"10.1016\/j.jtct.2024.04.017_bib0027","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2023020197","article-title":"Real-world evidence of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jtct.2024.04.017_bib0028","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1002\/cam4.4797","article-title":"Demographic differences among patients treated with chimeric antigen receptor T-cell therapy in the United States","volume":"11","author":"Emole","year":"2022","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.jtct.2024.04.017_bib0029","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.socscimed.2004.04.026","article-title":"Are racial disparities in health conditional on socioeconomic status?","volume":"60","author":"Farmer","year":"2005","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.jtct.2024.04.017_bib0030","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1146\/annurev-publhealth-040617-014230","article-title":"Relative roles of race versus socioeconomic position in studies of health inequalities: a matter of interpretation","volume":"39","author":"Nuru-Jeter","year":"2018","journal-title":"Annu Rev Public Health"},{"issue":"2","key":"10.1016\/j.jtct.2024.04.017_bib0031","doi-asserted-by":"crossref","DOI":"10.32892\/jmri.212","article-title":"Blacks\u2019 diminished health returns of educational attainment: health and retirement study","volume":"4","author":"Assari","year":"2020","journal-title":"J Med Res Innov"},{"key":"10.1016\/j.jtct.2024.04.017_bib0033","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","article-title":"Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial","volume":"29","author":"Houot","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.jtct.2024.04.017_bib0036","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2024.04.017_bib0034","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood-2021-146032","article-title":"Worsening financial toxicity among patients receiving chimeric antigen receptor T-cell (CAR-T) therapy: a mixed methods longitudinal study","volume":"138","author":"Cusatis","year":"2021","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724003701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724003701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T02:54:42Z","timestamp":1719975282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724003701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2666636724003701"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.04.017","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor T-Cell Access in Patients with Relapsed\/Refractory Large B-Cell Lymphoma: Association of Access with Social Determinants of Health and Travel Time to Treatment Centers","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}